Case 39-2008: A 51-year-old woman with splenomegaly and anemia

New England Journal of Medicine

Volumn 359, Issue 25, 2008, Pages 2707-

  Abramson, Jeremy S ^a,b   Chatterji, Manjil ^a,b   Rahemtullah, Aliyah ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; PARAPROTEIN; PHOSPHOLIPID ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD ANALYSIS; BONE MARROW BIOPSY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COOMBS TEST; DYSPNEA; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; LEG EDEMA; NIGHT SWEAT; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; URINALYSIS; ANEMIA; BLOOD; BLOOD CLOTTING DISORDER; BLOOD EXAMINATION; BONE MARROW EXAMINATION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; SPLEEN; SPLEEN TUMOR; SPLENECTOMY;

ANEMIA; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, ANTIPHOSPHOLIPID; BLOOD COAGULATION DISORDERS; BONE MARROW EXAMINATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMATOLOGIC TESTS; HUMANS; IMMUNOGLOBULIN M; LYMPHOMA; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PARAPROTEINS; SPLEEN; SPLENECTOMY; SPLENIC NEOPLASMS; SPLENOMEGALY;

EID: 58049206552     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0806981     Document Type: Article

References (41)

1. Beutler E. Lipid storage diseases. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams hematology. 7th ed. New York: McGraw-Hill, 2006:1009-14.
2. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-43.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: pathology and genetics of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001.
4. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-5.
5. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107:4643-9.
6. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950-6.
7. Chacon JI, Mollejo M, Muñoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648-54.
8. Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes: hematologic findings and outcomes in a series of 57 patients. Cancer 2004;101:2050-7.
9. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120:759-64.
10. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002;3:41-7.
11. Ciaudo M, Horellou MH, Audouin J, De Carbonnieres C, Conard J, Samama M. Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: a report of four patients. Am J Hematol 1991;38:271-6.
12. Martin SE, Abel RF. Splenic marginal zone lymphoma, iliac vein thrombosis, and monoclonal immunoglobulin M kappa antiphospholipid antibody with Annexin A5 interaction. Leuk Lymphoma 2006;47:1994-6.
13. Murakami H, Irisawa H, Saitoh T, et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol 1997;56:173-8.
14. Ziakas PD, Giannouli S, Tasidou A, Skopouli FN, Voulgarelis M. Multiple autoimmune phenomena in splenic marginal zone lymphoma. Leuk Lymphoma 2006;47:772-5.
15. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100:107-15.
16. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994;84:1620-7.
17. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-9.
18. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996;88:4265-74.
19. Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980;243:1909-11.
20. Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin Hematol 2005;42:156-64.
21. Kyriakou DS, Alexandrakis MG, Passam FH, et al. Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol 2002;14:1383-7.
22. Brody JI, Haidar ME, Rossman RE. A hemorrhagic syndrome in Waldenström's macroglobulinemia secondary to immunoadsorption of factor VIII: recovery after splenectomy. N Engl J Med 1979;300:408-10.
23. Endo T, Yatomi Y, Amemiya N, et al. Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia. Am J Hematol 2000;63:145-8.
24. Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997;96:850-3.
25. Mazurier C, Parquet-Gernez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand's syndrome in the course of Waldenström's disease. Thromb Haemost 1980;44:115-8.
26. Rao KP, Kizer J, Jones TJ, Anunciado A, Pepkowitz SH, Lazarchick J. Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma. Arch Pathol Lab Med 1988;112:47-50.
27. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994;84:3828-34.
28. Isaacson PG, Piris MA, Catovsky D, et al. Splenic marginal zone lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: tumours of the hematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001:135-7.
29. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a subgroup of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299-304.
30. Stamatopoulos K, Belessi C, Papadaki T, et al. Immunoglobulin heavy and light chain repertoire in splenic marginal zone lymphoma. Mol Med 2004;10:89-95.
31. Papadaki T, Stamatopoulos K, Belessi C, et al. Splenic marginal-zone lymphoma: one or more entities? A histologic, immunohistochemical, and molecular study of 42 cases. Am J Surg Pathol 2007;31:438-46.
32. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998;12:1141-66.
33. Idem. Coagulation, fibrinolysis and hypercoagulation. In: Henry JB, ed. Clinical diagnosis and management by laboratory methods. 20th ed. Philadelphia: W.B. Saunders, 2001:642-59.
34. Sawamura M, Yamaguchi S, Murakami H, et al. Multiple autoantibody production in a patient with splenic lymphoma. Ann Hematol 1994;68:251-4.
35. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731-6.
36. Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005;90:856-8.
37. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006;107:125-35.
38. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007;25:127-31.
39. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
40. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468-73.
41. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206-9.